The verdict
Our read at a glance.
Whether a cholinergic precursor with modest cognitive data is safe to take daily, given an observational stroke signal.
- The signal
- There is a legitimate clinical literature: choline alfoscerate is used as a prescription treatment for cognitive impairment in several countries and has been studied in Alzheimer's disease and vascular cognitive impairment, including in combination trials, with registered trials continuing. Effects are generally modest. The finding that dominates this memo is different in kind: a large population cohort study reported that alpha-GPC use was associated with a higher ten-year incident stroke risk in a dose-response manner after adjustment, a pattern that is harder to dismiss as confounding than a flat association would be. It remains observational, and the population studied was one with cognitive complaints.
- The unknown
- Whether the stroke association is causal. A dose-response relationship strengthens the case but does not settle it, and confounding by indication is a live alternative explanation since people prescribed it already have vascular risk.
- Our read
- The most under-discussed safety signal in the nootropic aisle. A modest cognitive effect, a plausible mechanism for harm, and a large cohort showing dose-dependent stroke risk - and it is sold as a pre-workout ingredient to people who have never seen that paper.
The mechanism
How it works.
Alpha-GPC is a choline-containing phospholipid that crosses the blood-brain barrier efficiently and is cleaved to release free choline, which is the substrate for acetylcholine synthesis. Raising central choline availability increases acetylcholine production in neurons that are limited by substrate, which is the basis for its use in cognitive impairment and for the nootropic claim - acetylcholine being central to attention and memory. The proposed route to harm runs through a different pathway. Choline compounds are metabolised by gut bacteria to trimethylamine, which the liver oxidises to trimethylamine N-oxide, and TMAO has been repeatedly associated with atherosclerosis and thrombotic risk. That gives a mechanistically coherent explanation for why a choline donor might raise stroke risk in a dose-dependent way, which is what the cohort data reported - though association, even dose-dependent association, is not the same as demonstration.
Safety & regulatory boundary
The consequential part.
Not an approved drug in the United States, where it is sold as a supplement; it is a prescription medicine in some other countries. The stroke signal is the reason this memo carries a safety watch, and the proposed mechanism - increased conversion to trimethylamine N-oxide, which is associated with atherosclerosis - is at least coherent. Anyone with existing cerebrovascular risk should treat this as an open question rather than a settled supplement.
What's next
What we're watching.
Replication of the stroke finding in other populations, and any trial with vascular endpoints.
Context
Why this is discussed.
It is one of the few nootropics with real prescription use abroad, and it appears in a large number of pre-workouts for a claimed effect on power output.
The evidence base
21 cited references.
Regulatory & labels1
Bestmade Natural Products (FDA label) · 2025
Registered trials8
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-03-16
ClinicalTrials.gov · NA · RECRUITING · 2025-10-21
ClinicalTrials.gov · NA · COMPLETED · 2024-01-09
ClinicalTrials.gov · NA · COMPLETED · 2022-12-09
ClinicalTrials.gov · PHASE4 · COMPLETED · 2018-04-01
ClinicalTrials.gov · NA · COMPLETED · 2021-04-01
ClinicalTrials.gov · EARLY_PHASE1 · UNKNOWN · 2022-03-22
ClinicalTrials.gov · NA · COMPLETED · 2019-03-25
Indexed literature (PubMed)12
Kansakar U et al. · Front Endocrinol (Lausanne) · 2023
Sagaro GG et al. · J Alzheimers Dis · 2023
Kerksick CM · Nutrients · 2024
Lee SH et al. · Brain Res · 2017
Lee W et al. · Medicine (Baltimore) · 2024
Li J et al. · J Food Sci · 2025
BAER E et al. · J Am Chem Soc · 1948
Greiner JV et al. · Exp Eye Res · 2020
Duong KL et al. · BMC Geriatr · 2024
Che X et al. · Nutr Rev · 2025
Choi JJ et al. · Nutrients · 2020
Min MH et al. · Drug Des Devel Ther · 2019
Keep reading